Loading cancer entity…
Loading cancer entity…
Clinical trials
792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | completed | Phase 2 | 29 | NYU Langone HealthOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00275028 |
| AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer |
| completed |
| Phase 2 |
| 47 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Nov 9, 2015 |
| clinicaltrials |
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | AmgenINDUSTRY | 3 | Oct 14, 2015 | clinicaltrials |
| NCT01313078 | Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2015 | clinicaltrials |
| NCT01764789 | Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer | completed | N/A | 39 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT00770536 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | completed | Phase 1 | 103 | AmgenINDUSTRY | 3 | Sep 29, 2015 | clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT01296035 | Panitumumab and Gemcitabine in Relapsed Ovarian Cancer(PanGem) | terminated | Phase 2 | 8 | Women and Infants Hospital of Rhode IslandOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT00003636 | Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 704 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Aug 5, 2015 | clinicaltrials |
| NCT01652794 | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01744821 | Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer | terminated | N/A | 7 | Northwestern UniversityOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT02478476 | DNA Single Nucleotide Polymorphisms as Predictors of Toxicity | unknown | — | 75 | OvaGene Oncology, Inc.INDUSTRY | 1 | Jun 23, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | terminated | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00060359 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 32 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2015 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00006981 | Immunotoxin Therapy in Treating Patients With Advanced Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00066651 | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT01196559 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 44 | The Catholic University of KoreaOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00388037 | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00959582 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 22, 2015 | clinicaltrials |
| NCT00415181 | Pharmacogenomics of Paclitaxel in Ovarian Cancer | completed | — | 93 | University of Southern DenmarkOTHER | 2 | Jan 13, 2015 | clinicaltrials |
| NCT00352300 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | completed | Phase 1 | 43 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00814086 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy | withdrawn | Phase 3 | 0 | Gynecologic Oncology GroupNETWORK | 0 | Dec 31, 2014 | clinicaltrials |
| NCT01294293 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 1 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT00003120 | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 3 | 308 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00550784 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 8 | City of Hope Medical CenterOTHER | 0 | Oct 7, 2014 | clinicaltrials |
| NCT00536523 | Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | — | 13 | University of MinnesotaOTHER | 1 | Aug 22, 2014 | clinicaltrials |
| NCT00052468 | Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer(AGO-OVAR9) | completed | Phase 3 | 1,742 | AGO Study GroupOTHER | 4 | Jun 25, 2014 | clinicaltrials |
| NCT00418093 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2014 | clinicaltrials |
| NCT00850772 | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer(OPEN) | completed | Phase 3 | 109 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Jun 12, 2014 | clinicaltrials |
| NCT01228942 | A Prospective Trial of COXEN Chemotherapy Prediction | withdrawn | N/A | 0 | University of VirginiaOTHER | 0 | Jun 6, 2014 | clinicaltrials |
| NCT00295945 | Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer | completed | — | 240 | University of California, San FranciscoOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00543049 | Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor | completed | Phase 2 | 73 | AGO Study GroupOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00504257 | Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma | completed | Phase 2 | 45 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 6, 2014 | clinicaltrials |
| NCT00989131 | Study of Paclitaxel in Patients With Ovarian Cancer | completed | Phase 3 | 789 | Oasmia Pharmaceutical ABINDUSTRY | 16 | Feb 4, 2014 | clinicaltrials |
| NCT00189553 | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse(CALYPSO) | completed | Phase 3 | 976 | ARCAGY/ GINECO GROUPOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003560 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 2 | 40 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT01131039 | Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Dec 20, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Dec 1, 2015source: clinicaltrials